Dr. Frangakis received his PhD in Biochemical Pharmacology from the University of Arizona and pursued postdoctoral research in cardiovascular physiology at the University of Alabama in Birmingham where he later joined the faculty in the department of Physiology and Biophysics in the school of Medicine. Dr. Frangakis joined the Sterling Winthrop Research laboratories as senior investigator where he worked in the discovery and development of (Amrinone & Milrinoe) the first phosphodiesterase inhibitors for the treatment of congestive heart failure.
Subsequently, Dr. Frangakis joined Glaxo Research laboratories where he was involved in leading programs in congestive heart failure, ischemic heart disease, and later in diabetes. In 1995, he joined the Licensing group at Bayer Pharmaceuticals where he was responsible for technology and research licensing in diabetes and metabolic diseases.
In 2000, he joined the Pharmaceutical Licensing and Business Development group at Johnson and Johnson where he has been responsible for licensing activities in the areas of metabolic and cardiovascular diseases for the last eight years. Beginning in January of 2009, Dr. Frangakis has been focusing his efforts in several new ventures including compound and platform spin-outs from his previous affiliation.
Charlene Dark has seized entrepreneurial opportunities throughout her entire career in the pharmaceutical research industry. Ms. Dark's experience has been focused in the CRO industry, where she began as a statistician and quickly grew to a leader of operations, strategic planning and business development. Ms. Dark has been instrumental in developing new departments and enhancing current divisions within existing organizations as well as leading the launch of new ventures for global and regional CROs. Ms. Dark is currently founder of C Dark Consulting, a professional services firm that focuses on business process optimization, organizational development, leadership, and project management in the pharmaceutical, biotechnology, medical devices, and CRO industries.